Cannabidiol — Membership Pricing

Other medications in Neurological

• Carbidopa-Levodopa
• Cladribine
• Clobazam
• Diazepam
• Diazepam Rectal
• Dimenhydrinate
• Dimethyl Fumarate
• Donepezil

About Cannabidiol

Cannabidiol, commonly known as CBD, is a prescription medication derived from cannabis that's primarily used to treat certain types of seizures and other conditions. While CBD has gained popularity in wellness circles, the FDA-approved pharmaceutical version offers proven therapeutic benefits. TheDrugClub members can access their prescribed cannabidiol medications with $0 co-pays and free home delivery, making treatment more affordable and convenient.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Cannabidiol is approved for (FDA label)

EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: May 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Cannabidiol (FDA label)

Cannabidiol oral solution: 100 mg/mL of a strawberry-flavored, clear, colorless to yellow solution. Oral solution: 100 mg/mL ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 8bf27097-4870-43fb-94f0-f3d0871d1eec. SPL document ID: 1eb7ac65-8df5-4a4a-9156-802cfaa92b06. Label effective date: May 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Cannabidiol (FDA label)

The following important adverse reactions are described elsewhere in labeling: • Hepatic Injury [see Warnings and Precautions ( 5.1 )] • Somnolence and Sedation [see Warnings and Precautions ( 5.2 )] • Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.3 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 )] • Withdrawal of Antiepileptic Drugs [see Warnings and Precautions ( 5.5 )] The most common adverse reactions (10% or more for EPIDIOLEX and greater than placebo) in patients with Lennox-Gastaut syndrome or Dravet syndrome are: somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder, and poor quality sleep; and infections. ( 6.1 ) The most common adverse reactions (10% or more for EPIDIOLEX and greater than placebo) in patients with tuberous sclerosis complex are: diarrhea; transaminase elevations; decreased appetite; somnolence; pyrexia; and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals, Inc. at 1-800-520-5568 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 8bf27097-4870-43fb-94f0-f3d0871d1eec. SPL document ID: 1eb7ac65-8df5-4a4a-9156-802cfaa92b06. Label effective date: May 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Cannabidiol (FDA label)

EPIDIOLEX is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product [see Description ( 11 ) and Warnings and Precautions ( 5.4 )]. Hypersensitivity to cannabidiol or any of the ingredients in EPIDIOLEX ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 8bf27097-4870-43fb-94f0-f3d0871d1eec. SPL document ID: 1eb7ac65-8df5-4a4a-9156-802cfaa92b06. Label effective date: May 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Cannabidiol (FDA label)

• Hepatic Injury: EPIDIOLEX can cause transaminase elevations. Concomitant use of valproate and higher doses of EPIDIOLEX increase the risk of transaminase elevations. See Full Prescribing Information for serum transaminase and bilirubin monitoring recommendations. ( 5.1 ) • Somnolence and Sedation: Monitor for somnolence and sedation and advise patients not to drive or operate machinery until they have gained sufficient experience on EPIDIOLEX. ( 5.2 ) • Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and thoughts. ( 5.3 ) • Hypersensitivity Reactions: Advise patients to seek immediate medical care. Discontinue and do not restart EPIDIOLEX if hypersensitivity occurs. ( 5.4 ) • Withdrawal of Antiepileptic Drugs: EPIDIOLEX should be gradually withdrawn to minimize the risk of increased seizure frequency and status epilepticus. ( 5.5 ) 5.1 Hepatic Injury EPIDIOLEX can cause dose-related elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]).

Source: FDA prescribing information (DailyMed). Set ID: 8bf27097-4870-43fb-94f0-f3d0871d1eec. SPL document ID: 1eb7ac65-8df5-4a4a-9156-802cfaa92b06. Label effective date: May 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Cannabidiol (FDA label)

• Strong inducer of CYP3A4 or CYP2C19: Consider dose increase of EPIDIOLEX. ( 7.1 ) • Consider a dose reduction of substrates of CYP1A2, CYP2C8, UGT1A9, and orally administered P-gp substrates. ( 7.2 ) • A lower starting dose of orally administered everolimus is recommended. ( 7.2 ) • Consider dose modification of CYP2B6 or CYP2C19 substrates. ( 7.2 ) 7.1 Effect of Other Drugs on EPIDIOLEX Strong CYP3A4 or CYP2C19 Inducers Concomitant use with a strong CYP3A4 and CYP2C19 inducer (rifampin 600 mg once daily) decreased cannabidiol and 7-hydroxy-cannabidiol (7-OH-CBD) plasma concentrations by approximately 32% and 63%. The impact of such changes on efficacy of EPIDIOLEX is not known [see Clinical Pharmacology ( 12.3 )] . Consider an increase in EPIDIOLEX dosage (based on clinical response and tolerability) up to 2-fold, when concomitantly used with a strong CYP3A4 and/or CYP2C19 inducer. 7.2 Effect of EPIDIOLEX on Other Drugs Antiepileptic

Source: FDA prescribing information (DailyMed). Set ID: 8bf27097-4870-43fb-94f0-f3d0871d1eec. SPL document ID: 1eb7ac65-8df5-4a4a-9156-802cfaa92b06. Label effective date: May 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.